Copper aspirinate Copper aspirinate Copper(II) aspirinate is an aspirin chelate of copper(II) cations (Cu). It is used to treat rheumatoid arthritis. Copper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid ("ASA") into salicylic acid and sodium acetate. The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu cations (copper(II) sulfate is suitable), precipitating bright blue crystals of copper aspirinate immediately. The crystals can
Dimercaptosuccinic acid with arsenic and mercury was first shown by I. Okonishnikova in 1962. In 1984, the now-defunct Bock Pharmaceutical Company requested the FDA grant approval for orphan drug status under the trade name Chemet and the FDA approved of this in 1991, providing exclusivity until 1998 which was conveyed to the successor Sanofi in 1996. Dimercaptosuccinic acid Dimercaptosuccinic acid (DMSA), also called succimer, is a medication used to treat lead, mercury, and arsenic poisoning. When radiolabeled with technetium-99m, it is used in a number of types of diagnostic testing. It is taken by mouth for 19 days. More than two weeks